1. 2019
  2. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma

    JULIET Investigators, Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Pantano, S., Pacaud, L. B., & 18 othersAwasthi, R., Chu, J., Anak, Ö., Salles, G., Maziarz, R. T., Study group members AMC, Kersten, M. J. J., Biemond, B. J., Burger, P., Claessen, M-J. J. A. G., Hazenberg, M. D., Kater, A. P., Kemper, E. M., Nur, E., Spiering, M., Tonino, S. H., Voermans, C. & Zeerleder, S. S., 3 Jan 2019, In: New England journal of medicine. 380, 1, p. 45-56 12 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. 2018
  4. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma

    Van Den Neste, E., André, M., Gastinne, T., Stamatoullas, A., Haioun, C., Belhabri, A., Reman, O., Casasnovas, O., Ghesquieres, H., Verhoef, G., Claessen, M-J., Poirel, H. A., Copin, M-C., Dubois, R., Vandenberghe, P., Stoian, I-A., Cottereau, A. S., Bailly, S., Knoops, L. & Morschhauser, F., 2018, In: Haematologica. 103, 5, p. 840-848 9 p.

    Research output: Contribution to journalArticleAcademicpeer-review

ID: 46924